Nicola George. Action on Hearing Loss.
Auris Medical also has another experimental drug called AM-101 in late-stage clinical testing for the treatment of acute tinnitus. When the sensory cells in the ear are exposed to trauma such as loud noise or toxins, they can send abnormal signals to the auditory nerve. These damaging signals are thought to be the start of some types of tinnitus. AM-101 works by blocking these damaging signals and the clinical researchers hope that by treating this early stage of tinnitus, longer term tinnitus will be prevented. People who have had tinnitus for less than 6 months can take part in the clinical trial in certain hospitals and ENT clinics across the UK. More information about the trial and how to take part can be found at the Tinnitus Study website.
In an earlier stage clinical trial in America, the biotech company Otonomy have begun testing their new drug OTO-311 for the treatment of tinnitus. Because this is the first time OTO-311 has been given to people (a “Phase 1” clinical trial), this study will be carried out in healthy volunteers first so that researchers can be sure that the treatment is safe. During 2016 they will test different doses of OTO-311 and if all goes well with this Phase 1 study, the company hopes to begin testing in people with tinnitus in the second half of the year.